nystatin-a1 and Cytomegalovirus-Infections

nystatin-a1 has been researched along with Cytomegalovirus-Infections* in 3 studies

Trials

2 trial(s) available for nystatin-a1 and Cytomegalovirus-Infections

ArticleYear
Hepatic allograft rejection under quadruple immunosuppressive regimen with cyclosporine A in liver transplantation: incidence of viral and fungal infection.
    Transplantation proceedings, 1994, Volume: 26, Issue:5

    Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Cyclosporine; Cytomegalovirus Infections; Drug Therapy, Combination; Female; Graft Rejection; Humans; Immunosuppression Therapy; Incidence; Liver Transplantation; Male; Methylprednisolone; Middle Aged; Muromonab-CD3; Mycoses; Nystatin; Prospective Studies; Transplantation, Homologous

1994
Prophylactic granulocyte transfusions during human bone marrow transplantation.
    The American journal of medicine, 1980, Volume: 68, Issue:6

    Thirty-eight uninfected patients undergoing bone marrow transplantation were assigned at random to receive prophylactic granulocyte transfusions and oral nonabsorbable antibiotics (group 1) or oral nonabsorbable antibiotics alone (group 2) when their neutrophil count fell below 0.5 x 10(9)/liter. The two groups were comparable in terms of age, sex, underlying disease, immunosuppressive therapy and days of neutropenia. There were three cases of septicemia (all due to gram-positive organisms) in group 2 and none in group 1 (p = 0.23). There was no difference in the incidence of other documented infections, and survival between the two groups was comparable. Recipients of prophylactic granulocyte transfusions had a significantly higher incidence of cytomegalovirus (CMV) infections (13 of 18 versus six of 17, p = 0.043). These data suggest that prophylactic granulocyte transfusions may prevent septicemia, have no effect on other infections or survival in patients undergoing bone marrow transplantation, and are associated with a higher incidence of CMV infection. Oral nonabsorbable antibiotics alone are equally effective in preventing serious infections in bone marrow transplant recipients.

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Blood Transfusion; Bone Marrow Transplantation; Child; Colistin; Cytomegalovirus Infections; Evaluation Studies as Topic; Female; Granulocytes; Humans; Infection Control; Male; Middle Aged; Neutropenia; Nystatin; Random Allocation; Transplantation, Homologous; Vancomycin

1980

Other Studies

1 other study(ies) available for nystatin-a1 and Cytomegalovirus-Infections

ArticleYear
Drugs for AIDS and associated infections.
    The Medical letter on drugs and therapeutics, 1995, Oct-13, Volume: 37, Issue:959

    Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiprotozoal Agents; Antiviral Agents; Atovaquone; Candidiasis, Oral; Clindamycin; Clotrimazole; Cryptosporidiosis; Cytomegalovirus Infections; Dapsone; Didanosine; Drug Combinations; Drug Therapy, Combination; Fluconazole; Flucytosine; Folic Acid Antagonists; Foscarnet; Glucuronates; Herpes Simplex; Herpes Zoster; Humans; Isoniazid; Itraconazole; Ketoconazole; Lamivudine; Mycobacterium avium-intracellulare Infection; Naphthoquinones; Nystatin; Pentamidine; Pneumocystis Infections; Pneumonia, Pneumocystis; Prednisone; Primaquine; Reverse Transcriptase Inhibitors; Stavudine; Syphilis; Toxoplasmosis; Trimetrexate; Tuberculosis; Zalcitabine; Zidovudine

1995